Affiliation:
1. Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523808, China
2. School of Medical Technology, Guangdong Medical University, Dongguan 523808, China
Abstract
Extracellular vesicles (EVs), as part of the cellular secretome, have emerged as essential cell–cell communication regulators in multiple physiological and pathological processes. Previous studies have widely reported that mesenchymal stromal cell-derived EVs (MSC-EVs) have potential therapeutic applications in ischemic diseases or regenerative medicine by accelerating angiogenesis. MSC-EVs also exert beneficial effects on other vasculopathies, including atherosclerosis, aneurysm, vascular restenosis, vascular calcification, vascular leakage, pulmonary hypertension, and diabetic retinopathy. Consequently, the potential of MSC-EVs in regulating vascular homeostasis is attracting increasing interest. In addition to native or naked MSC-EVs, modified MSC-EVs and appropriate biomaterials for delivering MSC-EVs can be introduced to this area to further promote their therapeutic applications. Herein, we outline the functional roles of MSC-EVs in different vasculopathies and angiogenesis to elucidate how MSC-EVs contribute to maintaining vascular system homeostasis. We also discuss the current strategies to optimize their therapeutic effects, which depend on the superior bioactivity, high yield, efficient delivery, and controlled release of MSC-EVs to the desired regions, as well as the challenges that need to be overcome to allow their broad clinical translation.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Guangdong Province
program for Training High-level Talents of Dongguan
Discipline Construction Project of Guangdong Medical University
Funds for PhD Researchers of Guangdong Medical University
Subject
Molecular Biology,Biochemistry
Reference138 articles.
1. A perivascular origin for mesenchymal stem cells in multiple human organs;Crisan;Cell Stem Cell,2008
2. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement;Dominici;Cytotherapy,2006
3. CD34+ stromal cells/fibroblasts/fibrocytes/telocytes as a tissue reserve and a principal source of mesenchymal cells. Location, morphology, function and role in pathology;Valladares;Histol. Histopathol.,2014
4. Is CD34 truly a negative marker for mesenchymal stromal cells?;Lin;Cytotherapy,2012
5. Human resident CD34+ stromal cells/telocytes have progenitor capacity and are a source of αSMA+ cells during repair;Aparicio;Histol. Histopathol.,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献